HONG KONG – Hong Kong-based gene therapy company Reflection Biotechnologies Ltd. received orphan drug designation from the U.S. FDA for its gene therapy, RBIO-101, to treat Bietti's crystalline dystrophy (BCD), an inherited eye disease affecting about 100,000 patients worldwide.